1589 - Long term hematopoietic cell transplant outcomes in patients at high risk for cytomegalovirus infections in the era of letermovir

Presenting Author(s)

• 

  Anthony J. Febres-Aldana, MD

  Clinical Fellow
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose

  Slides

Co-Author(s)

• AS

  Amy Spallone, M.D.

  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• FK

  Fareed Khawaja, MBBS

  Assistant Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• JS

  Joseph Sassine, MD

  Assistant Professor of Medicine
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• KS

  Krithika Srinivasan, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• 

  Oscar Morado Aramburo, MD

  Onco-Transplant ID Fellow
  The University of Texas MD Anderson Cancer Center
  houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• TS

  Terri Lynn Shigle, PharmD, BCOP

  Clinical Pharmacy Specialist
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): Takeda: Advisor/Consultant ()
• GR

  Gabriella Rondon, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): Omeros: Advisor/Consultant ()
• JR

  Jeremy Ramdial, MD

  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• ES

  Elizabeth Shpall, MD

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Disclosure: Disclosure(s): Adaptimmune: Advisor/Consultant (); Affimed: License agreement (); Axio: Advisor/Consultant (); Bayer Helathcare Pharmaceuticals: Honoraria (); Fibroblasts and FibrioBiologics: Advisor/Consultant (); Navan: Advisor/Consultant (); NY Blood Center: Advisor/Consultant (); Takeda: License agreement ()
• 

  Ella J. Ariza Heredia, MD

  Associate Professor
  The University of Texas MD Anderson Cancer Center
  Houston, TX, United States

  Disclosure: Disclosure(s): Merck & Co. Inc: Grant/Research Support (Ongoing)
• 

  Roy F. Chemaly, MD/MPH

  Professor
  MD Anderson
  Houston, Texas, United States

  Disclosure: Disclosure(s): Karius: Advisor/Consultant (), Grant/Research Support ()